Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis
NCT05353101Phase 1Completed
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Jul 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cyclosporine 2% ophthalmic solution in Vernal Keratoconjunctivitis (VKC) (2 arms), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoints: Changes of ocular signs at Day 60 and Changes of self-conscious symptoms at Day 60. Started Jul 2020; status: completed.
02
Drugs
cyclosporine 2% ophthalmic solution
03
Conditions
Vernal Keratoconjunctivitis (VKC)
Beyond the preview
Go deeper on NCT05353101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05353101.